UBC Faculty Research and Publications

EMPA-REG OUTCOME Trial : What does it mean? Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 107 explores the findings of the EMP-REG trial. Conclusions: The EMPA-REG OUTCOME Trial tested the addition of empagliflozin to a ‘standard of care’ for T2DM whose impact on clinically important outcomes is currently unknown. It is uncertain whether the reduction in mortality and serious adverse events in the EMPA-REG OUTCOME Trial is attributable to empagliflozin or to less use of other glucose-lowering therapies. The results of this trial are not applicable to people with T2DM in other clinical settings. Until there is a body of evidence informed by large, independently conducted comparative effectiveness trials of different therapeutic strategies, we will not know the optimal treatment of T2DM at various stages of the diagnosis.

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International